Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Miltenyi Biotec is one of the world’s leading providers of products and services for clinical research and cell and gene therapy (CGT). The company is committed to enabling the delivery of new treatment options to patients with unmet medical need. The company has more than 2,000 employees in 25 countries worldwide and its products have been used in more than 50,000 cell and gene therapy procedures.
Our state-of-the-art technologies and products provide integrated workflows for biomedical research and clinical applications, covering sample preparation, cell separation, cell activation, cell transduction and electroporation, cell culture, cell analysis and cell sorting.
We develop validated and tailored cell processing protocols for our GMP-compliant cell processing platform, the CliniMACS Prodigy®, to enable fully closed and automated manufacture of complex cellular products such as CAR T cells, TCR-transduced T cells, and gene-modified stem cells.
The company offers contract process development in Sunnyvale, CA, USA and Bergisch Gladbach, Germany, and manufacturing services for GMP manufacturing of CGT products based on its recognized platform technologies for cell processing and analytics. It also is a trusted provider of large-scale ancillary materials.
Lentigen, the wholly owned subsidy of Miltenyi Biotec, is a global provider of innovative solutions in biomedical research and cell and gene therapy. They are the leading experts for design, construction and production of lentiviral vectors.